Mankind Pharma (MANKIND) Q4 22/23 earnings summary

Executive summary

• FY23 revenue from operations grew 12.4% YoY to ₹8,749 crore, above IPM growth of 7.9%; volume growth was 2.6% versus flat IPM volumes.

• Domestic-focused scale remained a strength: 97% of revenue was domestic, with #1 prescription rank over six years and #3 volume rank in FY23.

• EBITDA and PAT declined amid higher API costs, employee expenses and Panacea integration costs; medium-term margin recovery is targeted.

Financial highlights

• Consolidated revenue from operations was ₹8,749 crore, up 12.4% YoY; EBITDA was ₹1,913 crore, down ~4.5%, and PAT was ₹1,310 crore.

• EBITDA margin was 21.9%, down 390 bps YoY; PAT margin was 15%, and basic EPS was ₹32 versus ₹35.8 in FY22.

• Cash flow from operations was ₹1,813 crore against capex of ₹832 crore; cash EPS was ₹40.4.

• Standalone revenue rose 8.6% to ₹8,127 crore; standalone PAT declined to ₹1,248 crore from ₹1,389 crore.

Outlook and guidance

• Medium-term operating margin target is 24%–26%; revenue growth ambition is 1.3x–1.4x IPM growth.

• FY24 priorities include expanding chronic therapies and Metro/Tier I reach, growing consumer healthcare, and pursuing launches, in-licensing and selective acquisitions.

• Consumer Healthcare is expected to sustain strong double-digit growth; chronic portfolio share is intended to rise further from 34% in FY23.